Is PT-141 (Bremelanotide) Legal in Alabama?

What Exactly Is PT-141 (Bremelanotide)?

PT-141 is the research-peptide name for bremelanotide, a synthetic cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Unlike phosphodiesterase-5 inhibitors such as sildenafil, bremelanotide works centrally in the hypothalamus rather than through vascular smooth muscle, which gives it a distinct mechanism for addressing sexual desire rather than purely physical arousal. Palatin Technologies originally studied the compound as PT-141 before it became the proprietary drug Vyleesi.

Mechanism of Action

Bremelanotide binds MC4R in the medial preoptic area and paraventricular nucleus of the hypothalamus. Animal studies showed MC4R activation increases dopaminergic tone in mesolimbic reward circuits, which translates clinically to increased sexual motivation. A 2019 pharmacology review confirmed that MC4R agonism modulates both desire and arousal pathways in rodent and primate models.

From Research Peptide to FDA-Approved Drug

The compound spent roughly two decades moving from preclinical study to approved drug. The key Phase 3 trials, RECONNECT Studies 1 and 2 (combined N=1,267), demonstrated that bremelanotide 1.75 mg produced statistically significant improvements in the Female Sexual Function Index desire domain score and a reduction in distress compared with placebo (P<0.001). The FDA granted approval on June 21, 2019, under the brand name Vyleesi. That history matters legally: once a compound becomes an approved drug, specific federal restrictions apply to compounding it.

Federal Legal Framework: FDA Approval and What It Means

The FDA approval of Vyleesi is the single most important legal fact about bremelanotide in any U.S. State, including Alabama. Federal law governs drug approval, compounding restrictions, and interstate distribution. State law layers on top of federal law but cannot create permissions that federal law prohibits.

FDA-Approved Drug Status

The FDA Center for Drug Evaluation and Research approved Vyleesi (bremelanotide injection, 1.75 mg/0.4 mL) under NDA 210557. The full prescribing information is available on the FDA accessdata portal. The indication is acquired generalized HSDD in premenopausal women. The label carries a boxed warning that bremelanotide can cause transient, clinically significant decreases in blood pressure and increases in heart rate. Prescribers must assess cardiovascular risk before initiating therapy.

Controlled Substance Status

Bremelanotide is not scheduled under the Controlled Substances Act. The DEA does not list bremelanotide as a Schedule I through V substance. This means a DEA registration is not required specifically for bremelanotide prescribing, though the prescriber still needs a valid state license and a legitimate patient-provider relationship.

The 503A and 503B Compounding Problem

This is where PT-141 / bremelanotide becomes legally complicated outside of the brand-name product. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a traditional compounding pharmacy may prepare a drug that appears on the FDA's "bulks list" or that uses a commercially available finished drug product as a starting point under specific conditions. The FDA's current 503A Bulks Substances list does not include bremelanotide. Compounding a drug that is essentially a copy of an FDA-approved product, and that is not on the bulks list, is generally not permitted under 503A without a documented clinical difference or individual patient need that the commercial product cannot meet.

Under 503B outsourcing facilities, the FDA maintains a separate list of bulk drug substances for large-scale compounding. Bremelanotide is not on that list either. A 503B facility that compounds bremelanotide without it appearing on the approved bulks list is operating in a legally gray zone and risks FDA enforcement action.

The FDA's guidance document on compounding of drugs that are copies of commercially available products spells out these restrictions clearly. Providers and patients in Alabama relying on compounded PT-141 from online sources that do not hold a valid 503A or 503B registration face real legal and safety risk.

Alabama State Legal Framework

Alabama does not have a separate state-level drug approval process. The state relies on federal FDA approval to determine what drugs are legal for prescribing and dispensing. State law governs who can prescribe (medical practice act), who can dispense (pharmacy practice act), and how compounding pharmacies must operate.

Alabama Medical Practice Act and Prescribing Authority

The Alabama Medical Licensure Commission regulates physician prescribing under the Alabama Medical Practice Act (Ala. Code § 34-24-1 et seq.). A licensed Alabama physician, physician assistant, or certified registered nurse practitioner with prescribing privileges may legally write a prescription for Vyleesi (bremelanotide 1.75 mg) for an appropriate patient. The Alabama Board of Medical Examiners publishes prescribing guidelines that align with federal standards for controlled and non-controlled substances. Because bremelanotide is not a controlled substance, the prescribing documentation burden is lower than for Schedule III or IV drugs, but a legitimate clinical encounter, documented diagnosis, and informed consent remain required.

Alabama State Board of Pharmacy and Compounding

The Alabama State Board of Pharmacy (ASBP) oversees all pharmacies operating in Alabama, including those that compound medications. ASBP enforces compliance with USP <795> (non-sterile compounding) and USP <797> (sterile compounding) standards. Because bremelanotide injection is a sterile preparation, any Alabama-based compounding pharmacy producing it must comply with USP <797> clean-room, testing, and beyond-use-dating requirements.

Alabama pharmacies that receive out-of-state compounded bremelanotide from a 503B outsourcing facility are required to verify that facility holds a valid FDA 503B registration. The FDA maintains an updated list of registered outsourcing facilities. Receiving or dispensing compounded bremelanotide from an unregistered facility violates both federal FDCA provisions and ASBP rules.

Telehealth Prescribing in Alabama

Alabama law permits telemedicine prescribing when the provider establishes a valid patient-provider relationship. The Alabama Board of Medical Examiners' telemedicine rules require that a provider conduct an appropriate evaluation, obtain informed consent, and maintain medical records consistent with in-person standards. A telehealth provider licensed in Alabama may therefore prescribe brand-name Vyleesi to an Alabama patient after a proper evaluation documenting HSDD. Prescribing compounded bremelanotide through telehealth carries the same 503A/503B restrictions described above.

The HealthRX clinical team uses a three-gate framework before authorizing any bremelanotide prescription in Alabama:

1. Gate 1, Indication check. The patient meets DSM-5 criteria for HSDD or a clinician-documented equivalent sexual desire complaint causing personal distress, consistent with the International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care recommendations.
2. Gate 2, Safety screen. Blood pressure, cardiovascular history, and current medication list reviewed for interactions, particularly with drugs that affect hemodynamics. The FDA label warns that bremelanotide caused mean maximum decreases of approximately 6 mmHg in systolic and 3 mmHg in diastolic blood pressure within 12 hours of dosing in clinical trials.
3. Gate 3, Product sourcing. Only brand-name Vyleesi or compounded bremelanotide from a verified FDA-registered 503A/503B pharmacy is authorized. Any product lacking a verifiable dispensing pharmacy with NABP accreditation is rejected.

Clinical Evidence Behind PT-141 (Bremelanotide)

Understanding the evidence helps providers and patients distinguish legitimate medical use from unsubstantiated off-label claims circulating online.

Phase 3 RECONNECT Trials

The RECONNECT program comprised two identically designed, randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized HSDD. Combined enrollment was 1,267 women; the primary endpoints were change from baseline in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. Bremelanotide 1.75 mg met both co-primary endpoints versus placebo in each study. The drug was dosed on-demand, not daily, which is clinically relevant for patient counseling.

Safety Data from Phase 3

Nausea was the most common adverse event, reported in 40% of bremelanotide-treated women versus 1% of placebo patients. Flushing occurred in 20% of bremelanotide-treated patients. The transient blood pressure changes resolved within 12 hours without treatment in most patients. The FDA label specifically states that bremelanotide should not be used in women with cardiovascular disease or uncontrolled hypertension.

Off-Label Use in Men

No FDA-approved indication exists for bremelanotide in men. Earlier clinical research explored its use in male erectile dysfunction, but a 2004 study published in the Journal of Urology (N=32) demonstrated dose-dependent penile erection in men with psychogenic erectile dysfunction. Prescribing bremelanotide off-label to men is not illegal, but providers must document the clinical rationale and inform the patient of the off-label status. Compounding bremelanotide specifically for male off-label use does not change the 503A/503B restrictions.

Comparison with Flibanserin (Addyi)

Bremelanotide is the second FDA-approved pharmacologic treatment for HSDD in premenopausal women; the first was flibanserin (Addyi), approved in 2015. A comparative review in the Journal of Sexual Medicine noted that flibanserin is taken daily and carries a boxed warning for severe hypotension with alcohol, while bremelanotide is taken on-demand and carries a blood pressure warning without an alcohol interaction restriction. Clinicians in Alabama may choose between the two based on patient lifestyle and comorbidity profile.

How to Get PT-141 (Bremelanotide) in Alabama Legally

Getting bremelanotide in Alabama through a legal, safe pathway involves four concrete steps.

Step 1: Identify a Licensed Alabama Provider

The provider must hold an active Alabama medical license (physician, PA, or CRNP with prescribing authority) or hold an active license in another state and comply with Alabama's telemedicine rules. The Alabama Board of Medical Examiners' online verification tool allows patients to confirm licensure status. A provider who prescribes without conducting a proper evaluation violates Alabama Code § 34-24-53, which prohibits prescribing without a legitimate clinical purpose.

Step 2: Complete a Proper Clinical Evaluation

For on-label use, the evaluation should document:

• HSDD diagnosis using DSM-5 criteria or validated tools such as the FSFI or FSDS-DAO
• Baseline blood pressure and cardiovascular history
• Current medications reviewed for hemodynamic interactions
• Discussion of non-pharmacologic options per ISSWSH process-of-care guidelines

Step 3: Obtain the Prescription at a Licensed Pharmacy

Brand-name Vyleesi is available at licensed retail pharmacies in Alabama. Patients may also use mail-order pharmacies licensed in Alabama. GoodRx and similar services list cash-pay prices for Vyleesi, which can exceed $800 per auto-injector; insurance coverage varies by plan. Patients seeking compounded bremelanotide should ask the dispensing pharmacy for its NABP e-Profile ID and confirm 503A accreditation. The NABP Verified Pharmacy Program list can be checked at nabp.pharmacy.

Step 4: Follow the Approved Dosing Protocol

The approved dose is 1.75 mg injected subcutaneously in the abdomen or thigh 45 minutes before anticipated sexual activity. The label advises no more than one dose in 24 hours and no more than approximately eight doses per month based on trial data. Patients should monitor blood pressure before the first dose if there is any cardiovascular history.

Risks of Obtaining PT-141 Outside Legal Channels

Online vendors sell "research-grade" PT-141 peptide vials, often labeled "not for human use," at prices far below Vyleesi's retail cost. Purchasing these products in Alabama carries multiple risks.

Legal Risk

Importing or purchasing an unapproved drug for personal use is not uniformly protected under FDA's personal importation policy. The FDA's personal importation policy applies only to products intended for serious conditions for which no U.S. Approved treatment exists. Because Vyleesi is FDA-approved, the personal importation exception does not clearly apply.

Safety Risk

A 2021 analysis of peptide products purchased from online research-chemical vendors found significant deviations from labeled concentration in 47% of samples tested, with some containing unidentified contaminants. Sterility cannot be assumed for products not manufactured under USP <797> standards.

Provider Liability Risk

An Alabama provider who writes a prescription knowing it will be filled by an unregistered compounder may face board action under Alabama Code § 34-24-360 (grounds for disciplinary action). The FDA has sent warning letters to compounding pharmacies distributing bremelanotide without adhering to 503A/503B requirements.

What Alabama's Regulatory Silence Does and Does Not Mean

Alabama has not passed a specific statute naming bremelanotide or PT-141. That silence does not create a legal free zone. It means state-level regulation defaults entirely to:

1. Federal FDA law on drug approval and compounding
2. Alabama Medical Practice Act on prescribing standards
3. Alabama Pharmacy Practice Act on dispensing and compounding

Any vendor claiming PT-141 is legal in Alabama because "Alabama has no specific law against it" is mischaracterizing how drug regulation works. The FDA's authority under 21 U.S.C. § 321 et seq. Covers all states; a state's failure to duplicate federal law does not suspend federal enforcement.

As the ISSWSH's 2019 consensus statement on bremelanotide states: "Bremelanotide is the first on-demand pharmacologic therapy approved for HSDD, and its use should follow the labeled indication, dose, and contraindications." That standard applies equally in Alabama.

Special Populations and Prescribing Cautions in Alabama

Postmenopausal Women

The FDA approved Vyleesi only for premenopausal women. Use in postmenopausal women is off-label. A pharmacokinetic study showed no clinically significant differences in bremelanotide exposure between pre- and postmenopausal women, but efficacy data in postmenopausal women are limited. Alabama providers prescribing off-label must document the clinical rationale.

Patients with Hypertension

The FDA label states that bremelanotide is contraindicated in patients with known cardiovascular disease, and that clinicians should consider whether the transient blood pressure effects are acceptable for each patient. Alabama has a hypertension prevalence of approximately 41% in adults according to CDC state-level data, making this contraindication clinically relevant in the state's patient population.

Patients Taking Naltrexone or Indomethacin

The FDA label identifies a drug interaction between bremelanotide and naltrexone, showing reduced naltrexone exposure of up to 35% when co-administered. Providers in Alabama treating patients on naltrexone for alcohol use disorder or opioid use disorder should carefully assess this interaction before prescribing bremelanotide.